The U.S. Food and Drug Administration said Wednesday it has sent warning letters to three baby-formula makers as part of what the agency called enhanced oversight of the product, which was plagued by

The Prognosis For Perrigo

03:08pm, Wednesday, 30'th Aug 2023
Perrigo Company plc provides over-the-counter health and wellness solutions after recently divesting its prescription businesses. Perrigo stock is reasonably valued at under 14 times forward earnings
DUBLIN , Aug. 24, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that CFO Eduardo Bezerra is scheduled to participate in one-
Perrigo Company plc (NYSE:PRGO ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Patrick Taylor - President and Chief E
Perrigo (PRGO) reports encouraging second-quarter 2023 results. Management reaffirms the financial guidance for 2023.
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Perrigo (PRGO) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.43 per share a year ago.
DUBLIN , July 25, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2023 financial res
Perrigo's birth control pill, Opill, can now be sold without a prescription. It'll likely start to nibble on the market shares of most other contraceptive methods.
Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.
Perrigo (NYSE: PRGO ) stock is rising on Friday as investors react to the company's over-the-counter birth control pill getting FDA approval. This is a major win for Perrigo stock as it marks the firs
The FDA just approved the first over-the-counter birth control pill -- Perrigo's Opill. There could be a significant demand for the OTC oral contraceptive.
Ibis Reproductive Health President Kelly Blanchard spoke with Yahoo Finance Live anchor Rachelle Akuffo about the FDA approval of Perrigo's Opill to be sold over the counter in the United States.
Yahoo Finance Live anchors Julie Hyman and Brad Smith break down the U.S. Food and Drug Administration approving Perrigo over-the-counter birth control pill named OPill. It is the first approval of an
Perrigo's Opill could significantly expand access to contraception, especially for younger women who often face logistical barriers to get birth control.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE